Reuters: Regulatory News: Impax settles lawsuit with Sanofi's Genzyme

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Impax settles lawsuit with Sanofi's Genzyme Sep 4th 2012, 12:32 Sept 4 | Tue Sep 4, 2012 8:32am EDT Sept 4 (Reuters) - Generic drug company Impax Laboratories Inc said it agreed to settle a lawsuit with French drugmaker Sanofi SA regarding the production and sale of the generic versions of two kidney disease drugs. According to the terms of the settlement, Sanofi unit Genzyme agreed to grant Impax a license to sell a generic version of Renvela tablets by March 16, 2014. Genzyme also agreed to license Impax to sell generic Renagel by Sept. 16, 2014. The two drugs had net sales of $392 million in the first half of 2012, Impax said in a statement. Impax shares closed at $23.67 on Friday on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions